Skip to content
Screener

Zymeworks ZYME Q3 2025 earnings

Reported November 6, 2025 · After market close

Revenue$27.6MBeat by $8.1M
EPS-$0.26Beat by $0.04
Revenue estimate$19.5M
EPS estimate-$0.30

Next report

Nov 5, 2026 (In 3 weeks)
Revenue estimate$227.4M
EPS estimate$2.29

Financials

Q3 2025

Income statement

See full
Revenue$27.6M+72.6%
Operating income-$22.1M+35.4%
Net income-$19.6M+34.3%
EPS (diluted)-$0.26+33.3%

Balance sheet

See full
Cash & equivalents$64.8M-47.0%
Total debt$18.9M-6.9%
Total equity$320.1M-12.8%
Total assets$397.3M-18.5%

Cash flow

See full
Operating cash flow-$31.4M-434%
CapEx$410.0K-54.4%
Free cash flow-$31.8M-369%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.29B+45.8%
Enterprise value$1.25B+58.9%
P/S9.6×-4.6×

Profitability

See full
Operating margin-52.5%-22.7pp
Net margin-47.2%-20.1pp
FCF margin-48.7%—

Returns & leverage

See full
Return on equity-18.5%-4.9pp
Debt / equity0.1×0.0×
Current ratio6.9×+2.8×

Segments

By product

See full
Drug supply for ongoing studies$970.0K-81.6%
Royalties$831.0K—
Development support payments$352.0K-53.9%
Other drug supply$71.0K-98.8%
Option exercise fee-—

FAQ

When did Zymeworks report Q3 2025 earnings?
Zymeworks (ZYME) reported Q3 2025 earnings on November 6, 2025 after market close.
What were Zymeworks's Q3 2025 revenue and EPS?
Zymeworks reported revenue of $27.6M and eps of $-0.26 for Q3 2025.
Did Zymeworks beat estimates in Q3 2025?
Revenue beat the consensus estimate of $19.5M by $8.1M. EPS beat the consensus estimate of $-0.30 by $0.04.
How did Zymeworks's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 72.6% from $16.0M a year earlier and eps grew 33.3% from $-0.39.
Where can I find Zymeworks's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001937653-25-000076) and the 10-Q periodic report (0001937653-25-000077) directly on SEC EDGAR. The filing index links above go to sec.gov.